FDA approves Celgene drug for pancreatic cancer

September 7, 2013

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

Abraxane is already approved to treat and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.

Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.

The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.

Explore further: Abraxane approved to treat advanced lung cancer

Related Stories

Abraxane approved to treat advanced lung cancer

October 14, 2012
(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people ...

Phase III worldwide study of new drug for patients with pancreatic cancer

November 19, 2012
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical ...

Experimental drugs for breast cancer could treat lung cancer too

August 13, 2013
Cancer Research UK -funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, reveals research published in Oncogene ...

FDA expands approval of Bayer cancer drug (Update)

February 25, 2013
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.

US approves radiation-based prostate cancer drug

May 15, 2013
(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

FDA approves genetic test for lung cancer drug

May 14, 2013
The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.